Navigation Links
The Neuropathy Association's Scientific Research Grants Focus: Autoimmune and Chemotherapy-Induced Neuropathies
Date:11/10/2008

NEW YORK, Nov. 10 /PRNewswire-USNewswire/ -- The Neuropathy Association has announced two awardees for its annual Scientific Research Grants Program.

Every year, The Neuropathy Association--a national patient-based non-profit organization dedicated to finding a cure for neuropathy--awards two scientific research grants, each for $80,000 over a two-year period.

This year's grant recipients--Gary J. Bennett, Ph.D. of McGill University (Quebec, Canada) and Helene Bour-Jordan, Ph.D. and co-principal investigator, Mark S. Anderson, M.D., Ph.D. of the University of California, San Francisco (UCSF) Diabetes Center--were chosen from eleven applicants involved in neuropathy research at medical institutions across North America.

Dr. Bennett's proposal, Mechanism of Paclitaxel-Evoked Peripheral Neuropathy, is based on data suggesting that paclitaxel (Taxol(R)) causes neuropathy by a novel and previously unrecognized mechanism. Paclitaxel is used by tens of thousands of patients as a first-line drug in the treatment of ovarian, breast and non-small cell lung cancer. The neuropathy, a serious side-effect of paclitaxel, can be severe---and often painful---thus preventing or limiting the use of the drug as an effective chemotherapeutic and leading to a decline in the patient's quality of life.

Dr. Bennett adds, "Preventing and controlling the neuropathy resulting from paclitaxel will, in turn, allow us to administer larger doses to more effectively kill cancer cells and save lives."

With their proposal, Identification of Neural Autoantigens in Autoimmune Peripheral Neuropathy, Drs. Bour-Jordan and Anderson hope to identify proteins of the peripheral nervous system that are targeted by the immune system in autoimmune neuropathy.

Dr. Bour-Jordan explains, "Autoantibodies in tissue-specific autoimmune diseases are excellent indicators of disease and are instrumental in identifying major autoantigens that are now used in clinical trials for several autoimmune disorders, including type 1 diabetes, multiple sclerosis and rheumatoid arthritis."

Ronnie Chalif, the Association's president affirms, "Finding a cure for neuropathy requires that we continue building upon our strategic research initiatives by making targeted investments in neuropathy research."

About Peripheral Neuropathy

Peripheral neuropathy is one of the most common diseases affecting approximately 20 million Americans.

Neuropathy results from injury to the peripheral nerves---the motor, sensory and autonomic nerves connecting the spinal cord to the muscles, skin, blood vessels and internal organs. It usually affects the hands and feet, causing weakness, numbness, lack of coordination or pain.

Approximately 30% of neuropathies are "idiopathic," meaning of an unknown cause; 30% are caused by diabetes. Other causes include autoimmune disorders, tumors, heredity, nutritional deficiencies, infections, trauma, and drugs or toxins.

About The Neuropathy Association

The Neuropathy Association(R), the leading national patient-based nonprofit organization, was established in 1995 by people with neuropathy and their families and friends to help those who suffer from disorders of the peripheral nerves. Now a national organization with over 50,000 members and supporters, 12 Association-designated neuropathy centers and 130 support groups, the Association's mission is to provide patient support and education, advocate for patients' interests, and find a cure for neuropathy.

For more information about peripheral neuropathy and The Neuropathy Association, visit http://www.neuropathy.org.


'/>"/>
SOURCE The Neuropathy Association
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. ReBuilder Medical Technologies, Inc. Contracts with ETS to Manufacture the Newest Version of its ReBuilder Neuropathy Treatment Device; Expects Sales to Increase 30%
2. Patient Enrollment Completed in Phase IIb Trial of EpiCept(TM) NP-1 in Diabetic Peripheral Neuropathy
3. Current and Emerging Therapies Have No Advantage Over Pfizers Lyrica in Their Effect on Patients Quality of Life in the Treatment of Diabetic Neuropathy
4. The Neuropathy Association Featured on NBCs Today Show as Part of National Neuropathy Week
5. The cause of all hereditary sensory and autonomic neuropathy type II cases has been established
6. Researchers provide genetic associations from a genome-wide scan for cardiovascular disease traits
7. Salugen to Present Research on Generational Associations of Reward Deficiency Syndrome at XVth World Congress on Psychiatric Genetics
8. Pharmacist Associations Partner to Increase the Voice of Pharmacy
9. Major Associations Band Together to Urge Congressional Action on Tobacco Legislation
10. American Heart Associations Announces Call for Entries for Howard L. Lewis Achievement Award
11. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... ... 16, 2017 , ... San Francisco dentist, Dr. Ben Amini , the ... device which is capable of taking digital impressions of teeth and gums. Conventional bite ... CAD CAM restorations , in terms of speed, efficiency and patient comfort. Increasingly, digital ...
(Date:1/15/2017)... ... January 15, 2017 , ... In this role, Courtney will ... States for the asthma & allergy friendly mark. This certification program was created by ... identify consumer products to be more suitable for the 60+ million people living in ...
(Date:1/15/2017)... ... January 15, 2017 , ... Accreditation Commission for Health ... its specialty care services. Albertsons Companies is the largest national food and ... pharmacy patients. , Accreditation by ACHC reflects Albertsons Companies’ dedication and commitment to ...
(Date:1/15/2017)... ... 2017 , ... Wondering where to go this Valentine's Day? Well, there is ... a romantic, lobster feast in the comfort of your own home. Lobster Gram is ... will be featured until February 15th, 2017. , Romantic Dinner one is Lobster ...
(Date:1/14/2017)... , ... January 14, 2017 , ... ... distinctions among their expanding line of activated charcoal products. With more and more ... of categorizing their products according to how they cater to specific needs. , ...
Breaking Medicine News(10 mins):
(Date:1/13/2017)... This morning, Stock-Callers.com draws attention ... fared at yesterday,s closing bell: Clovis Oncology Inc. (NASDAQ: ... GALE ), and ACADIA Pharmaceuticals Inc. (NASDAQ: ... processes to develop technologies and products that combat debilitating ... hungry, use less and cleaner energy, and provide safer, ...
(Date:1/13/2017)...  Secretary of Health Karen Murphy today ... at Misericordia University and discussed the Wolf Administration,s efforts ... . "The opioid epidemic is the ... my professional career," Secretary Murphy said. "This area of ... by heroin and prescription opioid overdoses. Across the commonwealth ...
(Date:1/13/2017)... Research and Markets has announced the addition of the ... offering. ... fibrosis (CF) is a progressive genetic condition and is the result ... (CFTR) gene from both parents. The defective CFTR genes produce faulty ... buildup of a thick and sticky mucus in the lungs and ...
Breaking Medicine Technology: